ISPC
iSpecimen Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.54
+0.00%Year over year
Reported trailing growth
- Revenue
- -92.1%
- EBITDA
- -28.0%
- EBIT
- +14.4%
- EPS
- +88.9%
- Free cash flow
- -33.1%
- Operating cash flow
- -20.8%
Forward estimates
Based on analyst estimates
- Revenue
- +2386.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -43.0%
- EBITDA
- +15.7%
- EBIT
- +29.5%
- Net income
- +16.1%
- EPS
- +87.0%
- Free cash flow
- +48.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026